X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (58) 58
humans (56) 56
index medicus (41) 41
kidney neoplasms - drug therapy (30) 30
cancer (29) 29
carcinoma, renal cell - drug therapy (29) 29
kidney neoplasms - pathology (28) 28
sunitinib (27) 27
middle aged (26) 26
male (25) 25
female (24) 24
interferon-alpha (22) 22
renal cell carcinoma (21) 21
treatment outcome (20) 20
aged (19) 19
carcinoma, renal cell - pathology (18) 18
metastasis (18) 18
carcinoma, renal cell (17) 17
sorafenib (16) 16
adult (14) 14
carcinoma, renal cell - secondary (14) 14
antineoplastic agents - therapeutic use (12) 12
hematology, oncology and palliative medicine (12) 12
quality of life (12) 12
antineoplastic agents - adverse effects (11) 11
care and treatment (11) 11
metastatic renal cell carcinoma (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
disease-free survival (10) 10
drug therapy (10) 10
kidney neoplasms - mortality (10) 10
medicine & public health (10) 10
survival (10) 10
targeted therapy (10) 10
aged, 80 and over (9) 9
carcinoma, renal cell - mortality (9) 9
prognosis (9) 9
chemotherapy (8) 8
indoles - adverse effects (8) 8
medical colleges (8) 8
neoplasm metastasis (8) 8
phase-iii trial (8) 8
protein kinase inhibitors - therapeutic use (8) 8
pyrroles - adverse effects (8) 8
therapy (8) 8
tyrosine kinase inhibitor (8) 8
vascular endothelial growth factor (8) 8
analysis (7) 7
axitinib (7) 7
double-blind (7) 7
efficacy (7) 7
everolimus (7) 7
indoles - therapeutic use (7) 7
kidney cancer (7) 7
molecular targeted therapy (7) 7
niacinamide - analogs & derivatives (7) 7
pazopanib (7) 7
pyrroles - therapeutic use (7) 7
sirolimus - analogs & derivatives (7) 7
survival rate (7) 7
aerobic exercise (6) 6
angiogenesis inhibitors - therapeutic use (6) 6
antitumor-activity (6) 6
carcinoma, renal cell - metabolism (6) 6
expression (6) 6
indoles - administration & dosage (6) 6
kidney neoplasms - metabolism (6) 6
open-label (6) 6
pyrroles - administration & dosage (6) 6
risk factors (6) 6
sirolimus - therapeutic use (6) 6
urology & nephrology (6) 6
antineoplastic agents (5) 5
cancer research (5) 5
carcinoma, renal cell - genetics (5) 5
carcinoma, renal cell - therapy (5) 5
docetaxel (5) 5
dose-response relationship, drug (5) 5
drug administration schedule (5) 5
endothelial growth-factor (5) 5
immunotherapy (5) 5
internal medicine (5) 5
kaplan-meier estimate (5) 5
medicine, general & internal (5) 5
medicine/public health, general (5) 5
pharmacology & pharmacy (5) 5
phase-ii trial (5) 5
rehabilitation (5) 5
survival analysis (5) 5
temsirolimus (5) 5
therapy management (5) 5
time factors (5) 5
trial (5) 5
tumors (5) 5
vascular endothelial growth factor a - antagonists & inhibitors (5) 5
angiogenesis inhibitors (4) 4
antimitotic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer Supplements, ISSN 1359-6349, 2013, Volume 11, Issue 2, pp. 172 - 191
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 2/2017, Volume 24, Issue 2, pp. 308 - 310
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2019, Volume 20, Issue 10, pp. 1332 - 1334
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 917 - 927
Journal Article
Current Opinion in Urology, ISSN 0963-0643, 01/2018, Volume 28, Issue 1, pp. 29 - 34
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 32, pp. 5204 - 5212
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2014, pp. e228 - e238
Journal Article
The Oncologist, ISSN 1083-7159, 03/2018, Volume 23, Issue 3, pp. 306 - 315
This review reports on the safety profile of cabozantinib in patients with advanced renal cell carcinoma and offers guidance on the management of adverse... 
Renal cell carcinoma | Cabozantinib | Adverse events management | TARGETED THERAPY | PHASE-III | NECROSIS-FACTOR-ALPHA | KINASE INHIBITORS | OPEN-LABEL | ANGIOTENSIN-II TYPE-1 | LUNG-CANCER | ONCOLOGY | COLORECTAL-CANCER | DOUBLE-BLIND | ENDOTHELIAL GROWTH-FACTOR | Genitourinary Cancer
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2010, Volume 36, Issue 5, pp. 416 - 424
Journal Article
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
Highlights • Survival of patients with mRCC has improved since the advent of targeted therapy. • Identification of prognostic biomarkers may advance... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGNOSTIC-FACTORS | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | OPEN-LABEL | PHASE-III TRIAL | INTERFERON-ALPHA | ONCOLOGY | DOUBLE-BLIND | 2ND-LINE TREATMENT | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic